Compare GSK plc (GSK) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? GSK plc trades at $46.63 (market cap $91.88B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.7 (market cap $25.27B). The key difference: GSK plc is far larger — about 3.6× Royalty Pharma plc Class A Ordinary Shares's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| GSK | RPRX | |
|---|---|---|
Market Cap | $91.88B | $25.27B |
Volume | 7,730,529 | 3,671,183 |
Sector | Health | Health |
52-Week High | $61.18 | $63.96 |
52-Week Low | $43.24 | $35.44 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $111.88B | $32.50B |
Dividend Yield | 3.9% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
